Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ibio (0JV0) Stock Price & Analysis

1 Followers

0JV0 Stock Chart & Stats

€0.68-€0.02(2.27%)
At close: 5:30 PM GMT+1
€1.2€1.3€1.4Jun 11Jul 8Jul 15Sep 4
Day’s Range
EUR 0.66 - EUR 0.68
52-Week Range
EUR 0.60 - EUR 2.62
Previous Close
EUR 0.66
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 42.50M
Enterprise Value
EUR 11.63M
Total Cash (Recent Filing)
EUR 76.65M
Total Debt (Recent Filing)
EUR 2.07M
Price to Earnings (P/E)
―
Beta
1.70
Next Earnings
Feb 16, 2027 (Est.)
EPS Estimate
-0.07
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage gives iBio greater financial flexibility than a heavily indebted biotechnology company. The modest debt burden may leave more capacity to fund research, withstand development setbacks, and pursue strategic financing while candidates advance.

Revenue Rebound

The sharp improvement in revenue indicates increasing commercial or partnering activity from a previously minimal base. Although still small, a stronger top line can improve operating leverage and provide evidence that the company is beginning to generate more business activity.

Differentiated Obesity Pipeline

The preclinical profile offers a potentially differentiated position in obesity by emphasizing fat loss and muscle preservation rather than weight reduction alone. Planned clinical entry could create a durable development catalyst if these benefits translate from primates to humans.

Bears Say

Persistent Large Losses

Losses remain exceptionally large relative to the current revenue base, showing that iBio’s research platform has not yet reached an economically self-sustaining scale. Persistent deficits can erode equity and require continuing external funding before products generate meaningful returns.

Continued Cash Burn

Heavy operating and free-cash-flow deficits mean the company must continue financing development and corporate activity through available capital or future issuance. This constrains strategic flexibility and makes progress dependent on maintaining funding through clinical milestones.

Weak Operating Economics

The modest gross margin and very wide gap between revenue and operating expenses indicate that current activities provide little absorption of the company’s cost base. Even with revenue growth, substantial scaling or successful product development is needed to improve profitability.

Ibio News

0JV0 FAQ

What was Ibio’s price range in the past 12 months?
Ibio lowest stock price was €0.60 and its highest was €2.62 in the past 12 months.
What is Ibio’s market cap?
Ibio’s market cap is €42.50M.
When is Ibio’s upcoming earnings report date?
Ibio’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 97 days.
How were Ibio’s earnings last quarter?
Ibio released its earnings results on Nov 10, 2026. The company reported -€0.045 earnings per share for the quarter, beating the consensus estimate of -€0.063 by €0.018.
Is Ibio overvalued?
According to Wall Street analysts Ibio’s price is currently Undervalued.
Does Ibio pay dividends?
Ibio does not currently pay dividends.
What is Ibio’s EPS estimate?
Ibio’s EPS estimate is -0.07.
How many shares outstanding does Ibio have?
Ibio has 60,853,560 shares outstanding.
What happened to Ibio’s price movement after its last earnings report?
Ibio reported an EPS of -€0.045 in its last earnings report, beating expectations of -€0.063. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Ibio?
Currently, no hedge funds are holding shares in DE:0JV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology